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In my findings, I have established a set series of protocols to recombinantly produce, 
purify and apply various fluorescent probes in vitro for the fluorescent labeling and study of the 
human immunodeficiency virus type 1 (HIV-1) envelope (Env) protein during HIV viral assembly. 
There remains insufficient knowledge about the molecular dynamics and interactions of HIV-1 
Env protein with its counterpart, Gag, on the inner host cell surface during assembly of a mature 
virus particle. There also remains an insufficient amount of data for the understanding and 
clarification of the mechanism of action of a known host cell HIV-1 restriction factor, Serinc5 (SER 
5), which is believed to have correlation with Env in fusion events.  
Using superresolution microscopy to measure and track host–pathogen interfaces that 
occur on a scale below the resolution limit of the light microscope is becoming increasingly 
popular. I have used total internal reflection microscopy (TIRF) and Photoactivated Localization 
Microscopy (PALM) to depict sites of molecular assembly via Env and Gag colocalization as well 
as measure and track other means of Env such as diffusion rates and host cell restriction factor 
interactions. 
Overall, my findings have provided improved strategies and tools for the use in 
fluorescently labeling and tracking HIV-1 Env and an HIV-1 host cell restriction factor known as 
SER 5. Superresolution microscopy and single particle tracking can be achieved provided high 
specificity, brightness and purity while maintaining low KDs. The production and data of these 
probes are imperative for both understanding the pathological processes of HIV-1 assembly and 
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Synopsis of the HIV/AIDS Pandemic 
 
a. The Discovery of AIDS and Initial Studies of HIV 
The current year of 2021 marks the 40th tragic anniversary of the beginning of the HIV/AIDS 
epidemic in the United States of America. Acquired immune deficiency syndrome (AIDS) is the 
illness caused by the Human Immunodeficiency Virus (HIV) which has claimed the lives of over 
42.2 million people globally and has recently been reported the sixth deadliest disease in the 
world (UNAIDS). 
During the spring of 1981, the Centers for Disease Control and Prevention (CDC) in Atlanta 
reported a surge in Pneumocystis carinii pneumonia and Kaposi’s sarcoma, both associated with 
an unknown acquired cellular immunodeficiency. The immune disorder in conjunction with the 
accompanying illness was soon thereafter defined as the acquired immune deficiency syndrome 
(AIDS). Along with Pneumocystis carinii pneumonia, AIDS patients were vulnerable to other life-
threatening opportunistic infections, such as complications caused by the Herpes Simplex Virus. 
In June 1981 shortly after taking notice of the surge, the CDC began national surveillance of this 
novel acquired immune disorder known as AIDS, as well as the other opportunistic diseases that 
arose associated with AIDS. By February 1983, 1,000 cases of AIDS were reported in the USA 
(Jaffe, Bregman and Selik, 1983; Siegal et al., 1981). 
After the AIDS had been discovered, researchers slowly began the marathon to discovery. In 
1982, both doctors and researchers observed that AIDS patients’ T-lymphocyte counts were 
(higher/lower) than those of healthy people. The depletion of the T-lymphocytes along with the 
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suppressed cellular immunity of these patients suggested that T cells could be a point of infection 
for the supposed infectious disease (Stahl et al., 1982). In 1983, another breakthrough in
research occurred in Paris when researchers discovered that AIDS was associated with a virus. 
At the Institut Pasteur, Departement de Virologie, a retrovirus belonging to the family of human T-
cell leukemia viruses (HTLVs), but unmistakably different from each previous isolate, was isolated 
from a patient with signs and symptoms that very commonly preceded AIDS, such as 
lymphadenopathy. This virus was noted to be significantly different than the previous HTLV 
isolates found by isolating antibodies from the patient’s serum and testing reactions with proteins 
from viruses of the HTLV-I subgroup. The antibodies reacted with HTLV-I viral proteins, but type-
specific antisera to HTLV-I did not precipitate proteins of the newly found viral isolate (Barre-
Sinoussi et al., 1983). This discovered T-cell tropic behavior and the reverse transcriptase activity 
that confirmed a retrovirus validation won Luc Montagnier and first author, Françoise Barré-
Sinoussi, the Nobel Prize in 2008 for the isolation and characterization of HIV-1. 
In 1984, scientists successfully isolated HIV-1 solely from AIDS patients and were not able to 
isolate the virus in healthy individuals. Only months later, this team rapidly developed a cell 
system using a human T cell line that produced these patient’s HIV-1 isolates in high yields, 
allowing for even further research advancement (Gallo et al., 1984; Popovic et al., 1984). 
Overall, it was Montagnier’s group that discovered this virus as the lymphadenopathy 
associated virus (LAV), it was Gallo’s group that further discovered the virus as human T-cell 
leukemia/lymphoma virus type IIIB (HTLV-III) and in 1986 the virus was declared the Human 
Immunodeficiency Virus (HIV) as we now know it today (Shilts, 1987). However, 40 years post 
discovery, there remains a high mortality rate and a search for the cure in the absence of a 





b.  Current Effects of the HIV/AIDS Pandemic  
Though the discovery of HIV-1 was a tremendous breakthrough that allowed scientists to 
study novel medicines and treatments, suffering remains. In recent surveillance results from 
2019, 25.4 million people were accessing antiretroviral therapy. 38.0 million people globally were 
living with HIV and 1.7 million people became newly infected with HIV. The same year, 690,000 
people died from AIDS-related illnesses.  Upwards of 100 million people have become infected 
with HIV since the start of the epidemic and 42.2 million of those people have died from AIDS-
related sicknesses and their complications since the start of the epidemic (UNAIDS, 2021).  
Data through June 2020 has shown a total of 26.2 million people were accessing 
antiretroviral therapy. In 2019, 25.6 million people were accessing antiretroviral therapy up from 
6.4 million in 2009. Overall, in 2019 still only 67% of all people living with HIV were accessing 
treatment. Totaling all people living with HIV, 81% knew their status, 67% were accessing 
treatment and 59% were virally suppressed in 2019 (UNAIDS, 2021).  
Medical cost estimates are often based on the health care utilization by persons with 
HIV/AIDS and can vary however in the U.S.A., the most recent published estimate of lifetime HIV 
treatment costs was $485,000 in the U.S.A (CDC, 2020). 
Given these points, HIV has caused alarming damage to humanity. As HIV-1 infections 
rise globally, economic barriers to treatment remain despite their availability, and HIV-1 will 











a. Treatable Stages 
Figure 1.1 Current Antiretroviral Treatments at Various HIV-1 Infection Cycle Stages.               
The text in blue labels the targets that are inhibited by existing treatments that have been 
approved by the FDA. Text in pink refers to the target with no current existing approved 
treatments. HIV follows this series of steps to multiply itself in the body. This mechanism begins 
when HIV interacts with a CD4+ T-cell and a CCR5 co-receptor. The seven steps in the HIV life 
cycle are: 1) binding; 2) fusion; 3) reverse transcription; 4) integration; 5) replication; 6) assembly; 
and 7) budding.  






















Figure 1.2. The Natural Progression of HIV After the Point of Infection (Before HAART) 
The immunopathogenic mechanisms of HIV without ARVs include the steady decrease in the 
host’s CD4+ immune cells while overlapping with a steady increase in viral RNA copies. For the 
entirety of an HIV infection, immunodeficiency progresses. Immunodeficiency begins to decline 
even while the disease symptoms are not present—Clinical Latency Period. At the point of 
expressing inherent symptoms of an HIV infection, the patient is diagnosed with AIDS.   Adapted 





























HIV Infection Cycle  
a. Retroviruses and an Overview 
HIV-1 belongs to the Retroviridae family and is typical of other retroviruses in life cycle 
behavior. Retroviruses are classified by their use of reverse transcriptase and their genomic RNA. 
An overview of retrovirus life cycle behavior consists of the virion that binds to host target cells via 
specific interactions between the viral envelope with receptors on the target host cells. The final 
product is progeny virions that bud off from the host cell plasma membrane, completing the 
reproductive cycle. 
b. Binding-Replication  
The first events of infection are known as fusion and entry. In order to enter the host cell, the 
virus requires at least 2 receptors —the CD4 molecule and a coreceptor, a chemokine receptor, 
such as CCR4 or CRCX5 (Choe et al., 1996). During membrane fusion, the virus is first 
introduced into the naïve host cell via the binding of the viral envelope glycoprotein gp120 to CD4 
on the targeted host cell. Upon binding, this will induce a conformational change in gp120 which 
yields a binding site for the chemokine receptor (Pier, 2004). The exposed binding site on gp120 
will then bind the chemokine receptor in the human host cell, inducing yet another conformational 
change to the correlative gp41. After the conformational change occurs in gp120, it then 
disengages from gp41 so that the fusion peptide can be inserted into the target plasma 
membrane (Furuta et al., 1998). The mechanism of insertion and fusion can be explained by the 
formation of a heat stable 6 helix bundle which drives this event (Melikyan et al., 2000). Upon 
fusion of gp41 with the targeted cell plasma membrane, the membrane is spanned by the helix 
complex and the viral core, capsid (CA), is released into the cytoplasm of the targeted human 
host cell where it then makes its way towards the nucleus. Upon CA entry, uncoating of the core’s 
subunits take place and interactions with host cell factors then begin as well as trafficking of the 
viral genome to the nucleus (Ambrose & Aiken, 2014). CA encases the viral RNA genome, 
reverse transcriptase, integrase, and proteases. Consequent to nucleus entry the viral RNA 
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contained within the core is reverse transcribed into viral DNA via reverse transcriptase (Pier, 
2004). Reverse transcriptase is an RNA dependent DNA polymerase and combined with the 2 
copies of single-stranded RNA genome will synthesize a single strand of DNA complementary to 
this viral RNA. Rnase H will then degrade this viral RNA, which then allows for synthesis of the 
second strand of DNA yielding double-stranded viral DNA (Pier, 2004). The viral ds-DNA 
translocates to the nucleus and is integrated via integrase into the host’s nuclear chromatin. At 
this point, the human host’s genome has now been “hijacked” by HIV. An important player to note 
during this stage is Rev, a protein of HIV-1 that goes back and forth between the nucleus and 
cytoplasm and contains a nuclear localization signal and a nuclear export signal, respectively and 
its primary function is nuclear import and export (Pollard & Malim, 1998). The virus can now use 
the machinery of the infected host cell containing integrated viral DNA, to create the building 
blocks for progeny virus. This stage is called replication within the HIV life cycle and is the last 
stage at which treatment exists for.  
c. Assembly and Maturation  
As mentioned above, the machinery of the infected host cell will be used by the virus from 
replication and proceeding steps. The newly formed viral DNA gests transcribed by 
commandeered host RNA polymerase II into splice-able full-length viral RNA (Purcell & Martin, 
1993). The nuclear protein Rev comes into play again and exports this newly transcribed viral 
RNA out of the nucleus and into the cytoplasm to serve as mRNA for translation into viral 
proteins. On a free ribosome, the gag glycoprotein precursor, Pr55Gag, is translated and 
produces Gag along with all of its structural components: matrix (MA), capsid (CA), nucleocapsid 
(NC) along with the P6 domain and 2 spacer peptides SP1 and SP2 (Adamson & Freed, 2007). 
The C-terminus of CA contains the protein dimerization interface while MA binds to the inner 
leaflet of the plasma membrane and oligomerizes to create a lattice (Mailler et al., 2016). Binding 
of MA to the host cell’s plasma membrane is driven by the post translational modification, known 
as myristylation, at the N-terminus. Myristylation allows for hydrophobic interactions with 
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membranes and the highly basic region at the surface of the membrane, which allows for 
electrostatic interactions with cellular lipids and membrane markers such as phosphatidylinositol-
4,5-bisphosphate (Chen et al., 2014; Olety & Ono, 2014). Plasma membrane association of the 
structural protein Gag, depends on its myristoylated matrix domain and this plasma membrane 
marker PI(4,5)P2. (Mücksch et al., 2017).  
Glycoprotein (gp) 160 is the primary Envelope glycoprotein complex gene product and it is 
cleaved by cellular protease furin, into gp120 and gp41 (Veronese et al., 1985). Env trafficks 
through the secretory pathway to the plasma membrane where it is displayed on the surface, 
gp120, and transmembrane protein, gp41 (Adamson & Freed, 2007). There are various models 
proposed for how Env and Gag interact at the surface to form a viral particle.   
Along with Env and Gag, the genomic RNA also needs to be recruited to sites of assembly 
for packaging into progeny virions. Single-molecule tracking via live cell fluorescence microscopy 
has shown that in the absence of Gag, the genomic viral RNA diffuses randomly within the cell, 
proving that it is not actively transported through the cytoplasm and that in fact, the RNA relies on 
Gag to traffic to the plasma membrane (Chen et al., 2014).  
After all required components have been recruited to the plasma membrane, the virus can 
now form a bud and be released from the plasma membrane. The PTAP motif in Gag allows 
the recruitment of Tsg101 and other ESCRTs to virus assembly sites where they mediate budding 
(Strickland et al., 2017). Tsg101 and ESCRT proteins are the players present to allow for the 
pinching off the bud so that it can be released into the host’s blood stream for new infections. 
The final stage of the viral life cycle of HIV-1 is known as maturation which occurs after 
assembly and release from host cells. Maturation is primarily comprised of morphological 
rearrangements of the virus particle forming the structural core and stabilizing the 2 strands of 
RNA (Sundquist & Kräusslich, 2012). The viral protease will cleave the Pr55Gag and Pr160Gag–
Pol precursors producing the structural components required for a new infection cycle. Once a 
10 
 
mature particle has formed, the cycle begins anew and gp120 then binds to CD4 on a new host 
cell and fusion and entry occur again.  
Fluorescent Labeling  
a. Modern State of the Art Strategies 
The microscope and light microscopy have allowed researchers the ability to visualize 
molecular details in biological systems since the 16th century however, superresolution 
microscopy has more recently overcome a resolution boundary known as the diffraction limit of 
light. Superresolution imaging has frequently and rapidly been evolving and can be applied to 
image cellular structures and protein-protein interactions in three dimensions, multiplex coloring, 
and single particle tracking in living systems with resolution down to a nanometer scale. More 
specifically, superresolution microscopy has been used to address the organizational structure, 
interaction, stoichiometry and dynamics of HIV-1 and several components involved in infected 
cells and tissues (Muranyi et al., 2013; Iliopoulou et al., 2018; Inamdar; 2019) 
Fluorescent superresolution microscopy has been crucial in the evolution of understanding 
the molecular and structural interactions as well as organizations of biological systems. With high 
molecular specificity and multi-color use capabilities, direct interactions can be seen between 
specifically labeled molecular species by observing co-localizations, distances, confirmation 
states etc. With low invasiveness, fluorescent superresolution microscopy serves as a perfect 
candidate for live cell imaging and the study of living systems (Sigal et al., 2018). 
To overcome the diffraction limit, the ability to distinguish molecules that reside within the 
same diffraction-limited volume is required (Sigal et al., 2018). Stochastic Optical Reconstruction 
Microscopy (STORM) is one technique used to overcome the diffraction limit of the Point Spread 
Function (PSF) of molecules that are being tracked, located, or measured. When two identical 
fluorophores are spaced apart in the lateral plane, also known as the x-y plane, and the distance 
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is greater than the diffraction limit these two spots can be differentiated and resolved. If they are 
too close then these fluorophores cannot be tracked separately and are overlapped (Pawley, 
2006). This then explains that the resolution of the microscope is limited by the width of the PSF 
and images that are under the PSF are unresolvable as single molecules, appear to be blurry and 
their localization cannot be correctly determined (Bates et al., 2013).  
b. Desirable Properties of a Molecular Probe 
To use STORM, a molecular probe must have the feature of photoswitchability—the ability to 
go between fluorescent and dark states and this must be controlled. If the entire population of 
probes switched on and off at the same time, then the same resolution issue would remain or lack 
thereof the ability to resolve. A cycle of activation, localization, deactivation, and plotting is 
performed repeatedly in order to determine resolved localizations of the blinking fluorophores 
(Bates et al., 2013). A high-resolution image can then be reconstructed from all of the plots and 
localization points collected during imaging and is no longer subjected to limitations by the 
diffraction limit of light however, it is limited to the number of photons collected and the amount of 
fluorophores that are actually labeling the sample (Thompson et al., 2004). 
Quantum yield is the measurement of the probability of the probe absorbing 1 photon and 
returning that photon back—the value of 1 being a complete return of photons. Therefore, the 
higher the quantum yield the better chances the molecular probe will not be dark. 
Another trait is the molar extinction coefficient (ε); depicting how well the chosen fluorophore 
absorbs at its peak wavelength. The product of the quantum yield and the molar extinction 
coefficient yields the brightness of the probe (Lakowicz, 2006).  These traits are important to the 
precision of each measurement in STORM because your precision is determined by the number 
of photons outputted from the activated fluorophore during a single cycle of blinking on and off 
(Bates et al., 2013). The less the number of photon output from your probe, the dimmer it will be 
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and vice versa which beautifully demonstrates the correlative product of quantum yield and molar 
extinction coefficient amounting to brightness. 
Due to the phenomenon of fluorescence, all fluorophores are excited and emit at different 
wavelengths, known as peak wavelengths, giving rise to the diversity of the selection of probes 
that can be used and this can be helpful to the researcher for reasons such as multiplexing. With 
the diversity of the visible light spectrum emitted from the fluorophore of choice, comes variability 
in the excitation wavelength as well. High-intensity light can be damaging to the cell itself and can 
also be phototoxic to the fluorophore. The main phototoxic effect is the result of the fluorophore 
becoming photobleached. Fluorophores cannot be excited unlimitedly and each time the probe is 
illuminated, a fraction of the population will be permanently destroyed.  Photobleaching, in 
general, cannot be avoided and is the limiting reagent that determines how many images can be 
acquired (Ettinger & Wittmann). Another limiting factor of photobleaching is the rate at which the 
fluorophore is bleached, also known as its photostability (Simonson et al., 2011). Photobleaching 
is not equivalent to photoswitchability of probes and is not turning them off, or switching to the 
dark state.  
Duty cycle is also an important factor to consider among molecular probes, depending on the 
microscopy technique approach. When using techniques that require a blinking probe, it is 
important to note that the probe will not be entirely in its on state or its off. Duty cycle refers to 
how long a fluorophore is in its on state/excited state in relativity to its dark state and the most 









Monoclonal Antibody Fragment: BG18 
Sources and Properties 
In search for broadly neutralizing antibodies used to control and reduce viremia, 
researchers recruited donors whose serum was monitored for neutralization of HIV over a period 
of time. Individuals develop antibodies after many years of chronic infection and only in 10-20% of 
infected people (Yacoob et al., 2016). A collaborative vaccine-based research group gathered a 
population of HIV-1 positive donors for this type of ELISA study and discovered BG18 in 2006.  
Donor EB354 received an HIV-1 diagnosis in 1986 and their antibodies were purified and first 
tested for neutralization starting in 2006 when the viral load was significantly lower than years 
previously documented (<400 copies/ml). At the end of this trial, 152 antibodies were found and 
formed 22 clones. Antibodies from 3 of the 22 clones were found to have the highest tier rating of 
neutralization activity. The 3 clones were then assessed further, and discovery revealed that 
antibody BG18 accounted for much of the serologic activity and the other 2 antibodies were 
significantly less potent (Freund et al., 2017). To date, BG18 is referred to as the most potent 
bnAb located at the N332-supersite (Steichen et al., 2019)  
Upon genomic comparison, BG18 was found to be very closely related to 2 previously 
isolated bNAbs directed against the V3 region of Env. The anti-Env antibodies related to BG18 
are 10-1074 and PGT121 (Mouquet et al., 2012; Caskey et al., 2017). The PGT121/10-1074 
family grouped the newly found BG18 into the V3/N332gp120 class of HIV-1 bNAbs (Walker et al., 
2011). This specific class of antibodies, including BG18, recognize both protein and glycan 
components on Env allowing for neutralization of most HIV-1 strains (Garces et al., 2015; Sok et 
al., 2016; Doores et al., 2015). BG18’s binding site on Env involves its CDR H3 loops, which 
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interact with the N332gp120 glycan and breaks through the glycan shield to also interact with a 
conserved peptide motif, GDIR, near the base of the V3-loop on the Env gp120 ectodomain 
(Pejchal et al., 2011; Gristick et al., 2016). 
To further understand BG18’s binding properties, a crystallization structure of BG18 has 
been solved. An X-ray free electron laser was used to overcome the limitations of crystal size and 
improve the resolution to 3.8 Å for a BG18-BG505-35O22 complex. BG18 and 35O22 were both 
in the fab form upon binding the BG505 Env in a trimer state. BG18 showed more protein surface 
contact with Env than any other PGT121-like antibodies (Barnes et al., 2018). Depicting the 
crystal structure of the BG18 fab has allowed for the reveal of an immunogenic epitope as well as 
a desirable target for a fluorescent probe. BG18 would be a preferable fab for the use of tracking 
HIV-1’s Env over a fab such as 35O22, because of its ability to bind to the outermost part of Env’s 
ectodomain on gp120 as opposed to the sterically hindered gp41 interface. 
Previously mentioned, it is important for a fab to contain a high affinity, or a low Kd value, 
when used in tracking methods. A binding assay for BG18 was performed at which complete 
BG18 Fab was captured in a 3-fold dilution series starting at 110 nM at 30 µL/s for 60 s and 
permitted to dissociate for 300 s against 8ANC195 IgG, a gp120-gp41 interface bNAb. Kinetic 
analyses allowed for the reveal of the ka, kd, and KD values for a 1:1 binding ratio (Barnes et al., 
2018). It was found the BG18 has a kd of 4 nm (Freund et al., 2017). This is a native BG18 kd to 
an HIV-1 Env trimer however, in a HIV vaccine design study, BG18 containing a mutation within 
the CDR H3 loop bound an Env trimer with a KD of near 2 pM (Steichen et al., 2019). The 
highlighted traits of BG18 such as its high affinity for HIV-1 Env’s gp120 N332 glycan, gives it a 











Figure 2.1. Cartoon portrayal of a crystal structure of natively glycosylated HIV-1 Env trimers 
bound with BG18. 
Cartoon representation of a formation of a clade A Env (gp120, light gray; gp41, dark gray) bound 
with BG18 Fab. High-mannose glycans (cyan) are represented as sticks, and complex-type 













Materials and Methods 
a. Cloning of BG18 Fab 
The pCOMB-3H-b12 plasmid is digested with SacI and NotI restriction enzymes for 12 hours 
at 37℃ and purified using a Monarch Gel Extraction Kit (NEB). BG18 light chain and heavy chain 
antibody amino acid sequences are accessible from the Protein Data Bank (PDBID: 6CH9) 
[Barnes et al.]. The fragment containing BG18 antigen binding sequences were synthesized (IDT; 
Coralville, IA, USA) and cloned into the pCOMB3H-b12 vector using SacI and NotI sites, 
replacing the b12 fab coding sequence (Barbas et al., 1994). The pIII region of BG18 Heavy and 
Light chain genes were amplified from a designed gBlock (IDR) with primers carrying SacI and 
NotI sites, containing pCOMB homology. Amplicons were ligated via Gibson reaction into the 
opened pCOMB vector. All sequencing was confirmed and validated through Quintara 
Biosciences.  
b. Test Expressions 
Immediately following DNA sequence validation, transformation of the pCOMB-3H-BG18 
plasmid is performed in Escherichia Coli XL1 Blue competent cells (Stratagene; San Diego, CA, 
USA). This strain is plated on LB agar containing the selective antibiotic, carbenicillin, and 
incubated overnight for approximately 16-18 hours at 37°C. A population of bacterial colonies 
(n>6), is selected for and each colony is inoculated into 1 X 5 mL LB broth media containing 
carbenicillin (100 µg/ml), tetracycline (15 µg/ml) and dextrose (.02 M). Incubation then occurs 
overnight at 37°C in a shaking incubator at ~220-250 RPM. After 16-18 hours, observe cultures to 
ensure a moderate amount of growth and biofilm production. Measure the OD600 and select for 
the culture amongst the population that nears the OD600 of 0.3 A. Once the ideal culture has been 
determined, discard the remainder of the population. The entire 5 mLs of the overnight culture will 
then be used to inoculate 2 x 50 mL Super Broth medium containing carbenicillin (100 µg/ml) and 
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tetracycline (15 µg/ml) in a 250-mL flask for appropriate aeration and 2 x 50 mL Luria Broth 
medium containing carbenicillin (100 µg/ml) and tetracycline (15 µg/ml) in a 250-mL flask for 
appropriate aeration. To inoculate, spin 5 mL cultures at 4,000 xg for 5 minutes, pour off and 
discard the supernatant and vortex pellet with 1 mL of Phosphate-Buffered Saline, pH 7.4 (PBS). 
Repeat this PBS cell wash step 3 times. After discarding the final wash supernatant, 1 mL of LB 
is added to the pellet which is then vortexed thoroughly. 250 uLs of vortexed culture is then 
added to the 50 mLs of SB and LB broth flasks and swirled to mix evenly. Cultures are then 
grown at 37°C until mid-log phase of growth (OD600 is approximately 0.6 A) which is a timed 
averaged of approximately 8 h After mid-log phase has been reached, 2 of the flasks will be 
removed from the 37°C and placed into a 30°C shaking incubator with equivalent RPM. Cultures 
are then shaken and grown overnight for 16-18 h The cells are harvested by normalizing the 
OD600 to the limiting culture and then pouring the cultures into 50 mL conical tubes and spun for 
20 min at 6,000 x g using a Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge 
(Thermo Scientific).  The pellet is then washed (3 X 30 mL [1X] PBS). Store the pellet at -80°C for 
at minimum of 1 hour. Note: storage time can be up to 1 year.  
Cellular lysates were produced by sonication in PBS pH 7.4 supplemented with 0.2 mM 
PMSF (Gold Biotechnology). Soluble proteins were clarified via centrifugation at 30,000× g for 30 
min and filtration by 0.22 μm cellulose acetate syringe filter. Use a large probe, preferably the 
300w Ultrasonic Homogenizer sonicator with the following settings: cycle 40% output power 1 
minute ON and 4 minutes OFF (Vevor). Centrifugation was performed using the same Fiberlite 
F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge (Thermo Scientific). Note: It is very 
important at this step to ensure your centrifuge balance is equivalent in mass to that of the 
sonicated lysate. Cell lysates can now be analyzed. 
c. Western Blot 
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After lysis, proteins are loaded and separated by a 13% polyacrylamide gel and transferred 
to a methanol activated PVDF membrane (GE Healthcare). The membrane is blocked for 24 
hours at 4ºC in PBSTM containing 5% milk and immediately probed overnight at 4ºC with gentle 
rocking. After 1-hour incubation with human-anti-Lclambda-HRP (Abcam), the protein levels are 
detected with SuperSignal Dura Luminol reagents (Thermo Scientific). 
d. Scale-up: Production of BG18 (1L) 
Construct used: N-terminal Light Chain gene with C-terminal His-6 tag on Heavy Chain in a 
pCOMB vector (ampicillin/carbenicillin resistance). 
Construct name: pCOMB3H-[BG18frz] 
The construct is newly transformed into E. coli XL1Blue cells or plated from a glycerol stock 
of freshly transformed XL1Blue cells (Stratagene; San Diego, CA, USA). The cells are plated out 
on LB-agar containing ampicillin (100 µg/ml) and tetracycline (15 µg/ml). Incubation then occurs 
overnight for 16-18 h at 37°C. A colony is selected from the plate to inoculate 1 X 5 mL LB 
medium containing carbenicillin (100 µg/ml), tetracycline (15 µg/ml) and dextrose (.02 M). 
Incubation then occurs overnight at 37°C in a shaking incubator between 220-250 RPM. At the 
point of overnight growth after , the 5 mL culture will then be used to inoculate 1 x 1 L Super 
Broth medium containing carbenicillin (100 µg/ml) and tetracycline (15 µg/ml) in a 2-L flask for 
appropriate aeration. After 16-18 hours, observe culture to ensure a moderate amount of growth 
and biofilm production. Measure the OD600 of culture and make note for future optimization. Ideal 
OD600 is approximately 0.3 A. The entire 5 mL of the overnight culture will then be used to 
inoculate 1 x 1 L SB broth medium containing carbenicillin (100 µg/ml) and tetracycline (15 µg/ml) 
in a 2 L flask for appropriate aeration. To inoculate, spin 5 mL culture at 4,000 xg for 5 minutes, 
pour off and discard the supernatant and vortex pellet with 1 mL of PBS. Repeat this PBS cell 
wash step 3 times. After discarding the final wash supernatant, 1 mL of LB is added to the pellet 
which is then vortexed thoroughly. The entire 1 mL of vortexed culture is then added via pipette to 
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the 50 mLs of SB broth and swirled to mix evenly. Cultures are then grown at 37°C until mid-log 
phase of growth (OD600 is approximately 0.6 A) which is a timed averaged of approximately 8 h 
After mid-log phase has been reached, the flask will be removed from the 37°C and placed into a 
30°C shaking incubator with equivalent RPM. Cultures are then shaken and grown overnight for 
16-18 h Harvest is performed by pouring the cultures into 500 mL centrifuge bottles and spun for 
20 min at 6,000 x g using a Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge 
(Thermo Scientific).  The pellet is then washed (3 X 30 mL [1X] PBS) and recollected into a 50 
mL conical tube. Store the pellet at -80°C for a minimum of 1 hour. Note: storage time can be up 
to 1 year.  
Cellular lysates were produced by sonication in PBS pH 7.4 supplemented with 0.2 mM 
PMSF (Gold Biotechnology). Soluble proteins were clarified via centrifugation at 30,000× g for 30 
min and filtration by 0.22 μm cellulose acetate syringe filter. Use a large probe, preferably the 
300w Ultrasonic Homogenizer sonicator with the following settings: cycle 40% output power 1 
minute ON and 4 minutes OFF (Vevor). Centrifugation was performed using the same Fiberlite 
F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge (Thermo Scientific). Note: It is very 
important at this step to ensure your centrifuge balance is equivalent in mass to that of the 
sonicated lysate. Cell lysate now contains solubilized BG18 to be purified via CaptureSelect CH1-
XL affinity chromatography resin (Thermo Scientific; Waltham, MA, USA). 
e. Incorporated Unnatural Amino Acid Production (1 L)  
Construct(s) used: N-terminal Light Chain gene with C-terminal Amber- His-6 tag on Heavy Chain 
preceding Ochre in a pCOMB vector (ampicillin/carbenicillin resistance). 
And a tRNA/tRNA synthetase pair for the in vivo incorporation of the negatively charged 
unnatural amino acid, p-azido-l-phenylalanine, onto BG18’s heavy chain in E. coli response to the 
Amber stop codon, encoded in a pEVOL vector (chloramphenicol resistance). 
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Construct(s) name:  pCOMB3H-BG18-LC-Amber-His6-Ochre and pEVOL-pAzF [1]. 
The constructs are newly co-transformed into E. coli XL1Blue cells or plated from a 
glycerol stock of freshly transformed XL1Blue cells (Stratagene; San Diego, CA, USA). The cells 
are plated out on LB-agar containing ampicillin (100 µg/ml), tetracycline (15 µg/ml) and 
chloramphenicol (33 µg/ml). Incubation then occurs overnight at 37°C. A colony is selected from 
the plate to inoculate 1 X 10 mL LB medium containing carbenicillin (100 µg/ml), tetracycline (15 
µg/ml), chloramphenicol (33 µg/ml) and a final concentration of .02 M dextrose. Incubation then 
occurs overnight for 18-18 h at 37°C in a shaking incubator at 220-250 RPM. The entire 10 mL of 
the overnight culture will then be used to inoculate 1 x 1 L SB broth medium containing 
carbenicillin (100 µg/ml), tetracycline (15 µg/ml) and chloramphenicol (33 µg/ml) in a 2 L flask for 
appropriate aeration. To inoculate, spin the 10 mL starter culture at 4,000 xg for 5 minutes, pour 
off and discard the supernatant and vortex pellet with 5 mL of PBS. Repeat this PBS cell wash 
step 3 times. After discarding the final wash supernatant, 1 mL of LB is added to the pellet which 
is then vortexed thoroughly. The entire 1 mL of vortexed culture is then added via pipette to the 1 
L of SB broth and swirled to mix evenly. Cultures are then grown at 37°C until mid-log phase of 
growth (OD600 is approximately 0.6 A) which is a timed averaged of approximately 5 h After mid-
log phase has been reached, 1 mM 4-Azido-L-phenylalanine (pAZF) was supplemented to the 
culture and expression of unnatural tRNAs and synthetase was induced with 2% (w/v) L-
arabinose (Gold Biotechnology; St. Louis, MO, USA). Cultures are then shaken and grown 
overnight for 16-18 h Harvest is performed by pouring the cultures into 500 mL centrifuge bottles 
and spun for 20 min at 6,000 x g using a Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall 
centrifuge (Thermo Scientific).  The pellet is then washed (3 X 30 mL [1X] PBS) and recollected 
into a 50 mL conical tube. Store the pellet at -80°C for a minimum of 1 hour. Note: storage time 
can be up to 1 year. BG18 fab that successfully suppressed the amber stop codon with pAZF was 
purified using Nickel affinity chromatography (Gold Biotechnology) followed by purification using 
CaptureSelect CH1-XL affinity chromatography resin (Thermo Scientific; Waltham, MA, USA). 
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Elution fractions were pooled and dialyzed overnight in PBS, pH 7.4. Expression was assessed 
by SDS-PAGE analysis on 4–20% gradient gel (Bio-Rad; Hercules, CA, USA). The final yields 
from 1–2 L of culture were typically in the range of 1–3 mg of BG18-pAzF. 
pEVOL-pAzF was a gift from Peter Schultz (Addgene plasmid #31186). 
f. Ni2+ Polyhistidine Affinity Chromatography Purification 
Cell lysis is to be performed in Buffer A, a solution adjusted to pH 8.0 containing 20 mM 
HEPES, 300 mM NaCl, 300 mM KCl and 20 mM imidazole. The Ni2+ resin is then equilibrated 
with Buffer A and batch incubated with the lysate over ice. To batch incubate, use desired amount 
of resin and resuspend 1 mL Buffer A and combine with cell lysate in 50 mL conical tube and rock 
slowly on ice for ≥ 1 h. Using a drip column, the resin is poured slowly to pack the column while 
the flowthrough is collected for future analysis. Wash the column with 12 column volumes of 
Buffer A solution, occasionally collecting flowthrough fractions for analysis. To elute, use 5 mL 
Buffer A containing 250 mM imidazole, collecting 1 mL fractions in 1.5 mL Eppendorf tubes. 
Elution fractions were pooled and dialyzed overnight in PBS, pH 7.4 with SnakeSkin dialysis 
tubing at 4°C (Thermo Scientific). Expression is assessed by SDS-PAGE analysis on 4–20% 
gradient gel (Bio-Rad; Hercules, CA, USA). Protein concentration can also be analyzed by 
calculating the absorbance at 280 nm and utilizing the Beer-Lambert Law. 
g. CH1-XL Affinity Chromatography Purification 
Create and pack a 0.5 mL resin bed of CaptureSelect CH1-XL affinity chromatography resin 
(Thermo Scientific; Waltham, MA, USA) in a Flex Column, equilibrated to room temperature with 
running buffer (Kimble). Running buffer consists of [1X] PBS, pH 7.4, .05% (v/v) TWEEN and 
.05% w/v sodium azide. Pour 20 mL cell lysate at a time over the resin bed carefully collecting the 
flowthrough. The column is washed with ≥ 300 mL running buffer before eluting the protein while 
simultaneously collecting flowthrough fractions. Ensure that the flow rate of running buffer does 
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not exceed 2 mLs/min. To elute the protein from the column, 5 mL .2 M glycine at a pH of 2.2 is 
slowly poured over the matrix and neutralized in 1 M Tris pH 9 to yield a collected fraction at a 
neutral pH of 7.4. Note: volume of the fraction is variable based entirely on preference. Elution 
fractions were pooled and dialyzed overnight in PBS, pH 7.4 with SnakeSkin dialysis tubing at 
4°C (Thermo Scientific). Expression is assessed by SDS-PAGE analysis on 4–20% gradient gel 
(Bio-Rad; Hercules, CA, USA). Protein concentration can also be analyzed by calculating the 
absorbance at 280 nm and utilizing the Beer-Lambert Law. 
h. DIBO Cu-free Click Reaction 
Copper-free click chemistry was performed between DIBO-QD625 (Site-Click kit, Thermo 
Scientific) and BG18-pAzF using a 1:1.5-fold stoichiometry, respectively. The reaction could 
proceed for 12–18 h at room temperature in the dark. Uncoupled DIBO-QD625 was removed 
from the reaction by another round of CaptureSelect CH1-XL affinity chromatography. Elution 
fractions were pooled and unreacted BG18-pAzF, lacking a DIBO-QD625 conjugate, was 
removed by filtration through a 100 Kda molecular weight cutoff filter (Site-Click kit) followed by 
repeated buffer exchanges with PBS, pH 7.4. 
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Figure 2.2. TIRF imaging of BG18-QD625 labeling Env-ΔCT trimers, and Gag CANTD-SkylanS 
nanobody expressed in live COS7 cells 
Multiple Env-ΔCT trimers (red) demonstrate mobile Env nature at Gag labeled HIV-1 assembly 
sites with CANTD-SkylanS nanobody (green). The high labeling density of BG18-QD625 
achieved, allows for improved quantification of Env single particle tracking during assembly 
events. Normalized and rendered to Gaussian peaks, width correspondence to uncertainty in 




















A Quantitative Live-Cell Superresolution Imaging Framework for Measuring the Mobility of 
Single Molecules at Sites of Virus Assembly 
Abstract 
The insurgence of superresolution microscopy into the fields of virology and microbiology has 
begun to enable the mapping of molecular assemblies critical for host–pathogen interfaces that 
organize on a scale below the resolution limit of the light microscope. It is, however, challenging 
to completely understand the molecular interactions between host and pathogen from strictly 
time-invariant observations. Herein, we describe a method using simultaneous dual-color 
superresolution microscopy to gain both structural and dynamic information about HIV-1 
assembly. Specifically, we demonstrate the reconstruction of single virus assembly sites using 
live-cell photo-activated localization microscopy (PALM) while concurrently assessing the sub-
viral mobility of the HIV-1 envelope glycoprotein during interaction with the viral lattice. We 
propose that our method is broadly applicable to elucidating pathogen and host protein–protein 
interactions through quantification of the dynamics of these proteins at the nanoscale. 
Introduction 
Since its inception, superresolution microscopy has been broadly adapted to many fields of 
biological study (Betzig et al., 2006; Hell, 2007; Rust et al 2006; Hess et al., 2006; Schermelleh et 
al., 2008). Such methods offer molecular specificity and resolution improvements up to 10-fold 
over conventional diffraction-limited microscopy, enabling the reconstruction of biological 
assemblies approaching tens of nanometers (Buttler et al., 2018). With these tools in hand, 
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researchers have been able to assess cellular spatial organization of molecular assemblies 
created by pathogens, enabling the nanoscale visualization of host–pathogen interfaces (Zhang 
et al., 2017; Han et al., 2014; Liu et al., 2018; Gray et al., 2016; Horsington et al., 2013; Hess et 
al., 2007; Laine et al., 2015; Floderer et al., 2018). In particular, superresolution imaging has 
provided powerful insight into the mechanisms of human immunodeficiency virus-1 (HIV-1) 
particle biogenesis and maturation (Buttler et al., 2018; Lehmann et al., 2011;  Chojnacki et al., 
2012; Pereira et al., 2012; Gunzenhäuser et al., 2012 Roy et al., 2013  Muranyi et al., 2013; Van 
Engelenburg et al., 2014  Hendrix et al., 2015 Boutant et al., 2020  Fogarty et al., 2014). While 
these studies have been powerful for uncovering new aspects of protein organization during HIV-
1 biogenesis, this methodology has been largely relegated to time-independent measurements 
and lacks spatiotemporal information regarding viral protein coalescence. These shortcomings 
have been addressed using fluorescence recovery after photobleaching (FRAP) to measure bulk 
diffusion rates for viral molecules, however, this technique cannot provide resolution below the 
the diffraction-limit (Sakin et al., 2017). Stimulated emission depletion microscopy in conjunction 
with scanning fluorescence correlation spectroscopy (STED-FCS) presents a route to measure 
diffusion rates of viral molecules below the resolution limit of the light microscope (Chojnacki et 
al., 2017). In addition, single particle tracking (SPT) is an orthogonal and readily accessible 
method that can provide spatiotemporal information of single viral molecule dynamics on the 
scale of one to tens of nanometers (Pezeshkian et al., 2019). Combinations of both STED and 
SPT have also been demonstrated (Inavalli et al., 2019). 
Upon infection, HIV-1 Gag oligomerizes on the inner leaflet of the plasma membrane in T-
cells by a cooperative interaction between its N-terminal membrane-binding domain and internal 
Capsid (CA) oligomerization domain(Saad et al., 2006; Alfadhli et al., 2009; Ono et al., 2004;  Li 
et al., 2000; Gamble et al., 1997). After reaching a critical mass of oligomers, the forming lattice 
will buckle the plasma membrane to create a virus bud (Jouvenet et al., 2008; Ivanchenko et al., 
2009). To form an infectious particle, the HIV-1 envelope glycoprotein (Env) must traffic from the 
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biosynthetic pathway to reach the plasma membrane. Upon reaching the plasma membrane, Env 
freely diffuses and either becomes trapped in a newly formed Gag lattice or is endocytosed 
(Checkley et al., 2011; Byland et al., 2007). Previously, we described the spatiotemporal 
dynamics of HIV-1 Env on a sub-viral scale (tens of nanometers) during HIV-1 biogenesis on 
living cells (Pezeshkian et al., 2019). Our SPT method allowed for simultaneous measurement of 
heterogeneous diffusion modalities and trapping of Env at sites of Gag lattice formation, which 
was dependent upon residues in both Gag and Env. Our previous approach relied on 
conservative estimates of Env proximity to Gag lattices due to diffraction-limited resolution of 
virus assembly sites, creating uncertainty in the location of the perimeter of these assembly sites. 
For strong phenotypic differences this uncertainty becomes negligible, however, this error 
becomes significant as genetic phenotypes become more nuanced. Herein, we expand on our 
previous methodology by providing a framework for measuring live-cell nanoscale dynamics 
using superresolution photo-activated localization microscopy (PALM) of the Gag lattice paired 
with single particle tracking of HIV-1 Env. Although we have focused this methodology on HIV-1 
assembly, this method is broadly applicable to other virus species and microbial receptor 
interactions. 
Results 
2.1. Simultaneous Superresolution Reconstruction and Tracking of HIV-1 Gag and Env 
To track HIV-1 Env with respect to sites of virus assembly on the plasma membrane of living 
cells, we used total internal reflection fluorescence microscopy (TIRF-M) with simultaneous dual-
wavelength monitoring. To reconstruct sites of Gag assembly below the diffraction-limit of the 
light microscope, we used a genetically encoded Camelid antibody (nanobody), targeting the 
Capsid (CA) domain of Gag, fused to the photoswitchable fluorescent protein Skylan-S (Helma et 
al., 2012; Zhang et al., 2015), and expressed from the viral genome. Previously, we 
demonstrated that the CA nanobody has no known perturbing effects on the formation of virus 
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particles (Pezeshkian et al., 2019). We screened several green photoswtichable fluorescent 
protein variants from the Skylan series and selected Skylan-S (mEOS3.1 parent with H62S 
mutation) as it displayed ideal photoswitching rates and photon output for our desired frame rate. 
Unlike mEOS3.1, Skylan-S does not undergo photoconversion from a green to red form (Zhang 




Figure 3.1. CA-Skylan-S probes accurately reconstruct HIV-1 assembly sites on live infected 
T-cells. (A) The HIV-1 Gag lattice (Gray) oligomerizes on the inner leaflet of the plasma 
membrane (Blue). The genetically encoded anti-CA nanobody fused to Skylan-S (CA-Skylan-
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S) binds specifically to the N-terminal domain of Capsid. Skylan-S undergoes photoswitching 
upon illumination with blue (473–488 nm) laser light, moving single Skylan-S molecules 
between a ‘Dark’ and ‘On’ fluorescent state (black and green, respectively). (B) Example of 
localization accumulations for a single diffraction-limited virus assembly site on a live infected 
CEM-A cell expressing CA-Skylan-S probes. Green represents ‘On’ molecular localizations 
accumulated over time. Black represents the final accumulation of localizations for the 
reconstructed virus assembly site. Curves are the respective probability densities in 
horizontal and vertical directions (X,Y) for the superresolution reconstruction showing a 
Gaussian-like distribution after sufficient sampling of lattice-associated CA-Skylan-S probes. 
(C) Aggregate of all uncertainties in position for each localization in all data sets is 
demonstrated (σ). The histogram was fit to a bimodal Gaussian probability density 
(μσlow=32.9±8.9,μσhigh=68.9±18.2 nm). The larger peak was eliminated by filtering 
localizations to σ<40 nm and likely represents localization events in areas of high cellular 
background. (D) Assembly sites on the surface of live CEM-A T-cells were reconstructed 
using the localization centroids with their respective uncertainties (scale: Image = 5 μm, Inset 
= 200 nm. Maximum localization density: 0.7 localizations per nm2). (E) Full-width at half-
maximum (FWHM) for segmented virus assembly sites (normal distribution 
fit: μXFWHM=139.8±30.5 nm; μYFWHM=137.7±31.3 nm; fit not shown). FWHM in both 
coordinates converge on the theoretical size of HIV-1 particles, demonstrating the ability of 














Specifically, these single fluorescence events are captured during high-speed streaming 
and can be subsequently fit to a Gaussian function to determine the position of the 
fluorescent probe. This centroid and the number of integrated photons are used to determine 
the uncertainty in the position measurement (Betzig et al., 2006) (Figure 6B,C). The 
accumulation of these points and their uncertainties in time enables the reconstruction of the 
Gag lattice below the diffraction-limit using the live-cell PALM method (Shroff et al., 2008) 
(Figure 6D). To determine whether assembly sites were reconstructed to the approximate 
size of an HIV-1 particle in 2-D cartesian coordinates, they were fit to a normal distribution 
and full-width at half maximum (FWHM) was calculated. The approximate size of the HIV-1 
virus particle is ≈145 nm (Briggs et al., 2003), which validates 138 ± 31 nm as our mean 
FWHM of assembly sites (Figure 6E). We found that membrane movement and microscope 
drift were negligible during rapid acquisition (100 frames per second (fps); 30 s interval) as 
FWHM reconstructions between x and y dimensions varied by 5.8 nm (4%) for each 
assembly site measured. Importantly, simulations of our experimental system suggest that 
our FWHM reconstructions of virus assembly sites results from the localization of more than 
one CA-Skylan-S molecule. 
To visualize single Env trimers diffusing proximal and incorporating into Gag assembly 
sites, we labeled Env trimers with a modified anti-Env antibody fragment (fab) conjugated to 
a quantum dot. The anti-Env fab, BG18, has nanomolar affinity for the glycan-V3 region of 
the gp120 ectodomain of Env (Freund et al., 2017). The fab was produced recombinantly in 
bacteria in order to incorporate an unnatural amino acid, p-azido-L-phenylalanine, capable of 
reacting site-specifically to a dibenzocyclooctynol (DIBO)-modified quantum dot via copper-





Figure 3.2. BG18-QD625 design and production 
Recombinant bacterial expression system for production of BG18 containing an unnatural 
amino acid (UAA). E. Coli strains selected for both pCOMB3H-BG18-Amber fab and H-4-
azido-phenylalanine(pAzF) tRNA/ tRNA-synthetase expression plasmids produce UAA-
incorporated light chain BG18 upon pAzF-charged tRNA anticodon (AC) recognition of the 
Amber stop codon. (B) The incorporation of the UAA allows for noncanonical expression of 
p-azido-L-phenylalanine thereby, providing a site for a quantum dot click reaction as well as 
a His-(×6) tag for purification of UAA-incorporated fab (R = BG18 fab). (C) Cartoon protocol 
for the purification of BG18-QD625: (1) Metal-ion affinity chromatography of Amber-
suppressed BG18 fab possessing a hexahistidine repeat after the pAzF UAA, (2) purified 
BG18-pAzF fab is then conjugated to DIBO-QD625 using copper-free click chemistry, (3) 
unreacted DIBO-QD625 is subsequently removed from BG18 fab by affinity chromatography 
using anti-human IgG CH1-domain resin, (4) unlabelled BG18-pAzF fab is then removed 
from the BG18-QD625 conjugates using a 100 kDa molecular-weight cutoff filter. (D) 
Molecular cartoon of the BG18-QD625 conjugation strategy using the copper-free click 
chemistry reaction. The covalent coupling reaction occurs between the strained alkyne group 
and the azide moiety. (E) SDS-PAGE of flowthrough, wash, and elution fractions after BG18 
purification from both metal-ion and CH1XL affinity chromatography. Heavy and light chains 
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of fab complexes are purified to near homogeneity in stoichiometric abundance as assessed 





Figure 3.3. BG18-QD625 is a highly specific monovalent probe for high-density localization of 
single HIV-1 Env trimers.  
34 
 
(A) HIV-1 Env diffuses freely on the plasma membrane until encountering a Gag lattice. BG18-
QD625 (Magenta) binds to a glycopeptide (V3) on the HIV-1 Env gp120 ectodomain. The gp120 
domain non-covalently associates with the ectodomain of gp41, which is anchored to the 
membrane through the transmembrane and Cytoplasmic Tail (CT) domains, with the CT 
putatively interacting with or sterically trapped by the Gag lattice. (B) Temporal point localization 
of a single Env trimer reconstructs a diffusion trajectory. Magenta stars represent new 
localizations of a single BG18-QD625 probe per frame. Black represents the entire accumulation 
of localizations over the time of acquisition. Curves represent the probability densities in 
horizontal and vertical (X,Y) dimensions for sub-diffraction limited distributions of mobile trimers 
labeled by BG18-QD625. (C) The localization precision of BG18-QD625 labeled Env trimers is 
σ=16.1±6.6 nm, equating to roughly 10% of the diameter of a single virus particle, allowing for 
mobility measurements at a sub-viral scale. (D) Tracking of single Env trimers on living cells 
demonstrates that Env has a range of mobility distributions. The maximum density of localizations 
is 13.2 localizations per nm2 (magenta color bar) over 30 s of sampling. Inset shows a highly 
confined Env trimer displaying an apparent normal distribution of displacements (inset scale bar 
is 200 nm; full image scale bar is 5 μm). (E) Single molecule trajectories of Env classified as 
proximal to sites of assembly were fit to a normal curve and the FWHM was calculated (fits not 
shown). These tracks proved to be highly confined at the sub-viral level 
(μXFWHM=103.3±43.2nm and μYFWHM=111.0±52.2 nm). Clusters of Env localizations were 
found to be 30% smaller than the average size of virus assembly sites. This suggests that Env 














Conjugation of the fab to Quantum Dot 625 (QD625) provided a mean localization precision of 
16.1 ± 6.6 nm at 100 fps when bound to surface exposed Env (Figure 8C). With high 
spatiotemporal resolution and sparse cellular labeling of Env using the BG18-QD625 probe, we 
were able to visualize and quantify sub-viral confinement of Env within single reconstructed Gag 
lattices (Figure 6D and Figure 8 B). No significant cross-talk between the two fluorescent 
channels was observed and QD625 fluorescence intensity remained relatively stable during 
imaging intervals. Env in proximity to Gag centroids were fit to a normal distribution to assess the 
FWHM of confinement. The mean FWHM of Env positional measurements within the viral lattice 
was 101 ± 48 nm, corresponding to 73 percent of the average size of viral assembly sites 
measured by live-cell PALM (Figure 8E). 
2.2. Sub-Viral Quantification of Env Diffusion 
With our results suggesting that single Env trimers in proximity to the Gag lattice have some 
sub-viral mobility, we then sought to quantify the differences in mobility between Gag lattice 
proximal and distal Env trimers. Trimers were deemed proximal to a Gag lattice if they were found 







where FWHM-X/-Y are the virus assembly site dimensions, σ FWHM is the standard deviation of 
the FWHM distribution, and σ registration is the error in alignment of the Env and Gag fluorescent 
channels. In regions void of a Gag lattice ROI, Env tracks were classified to be distal. We 
quantified the differences in mobility between proximal and distal single Env trimers by first linking 
Env localizations based on proximity to one another and their frame interval (see Materials and 
Methods for track linking description). We observed marked differences in track appearance and 
shape between proximal and distal tracks, with distal tracks displaying random-walk or Brownian-


















Figure 3.4. HIV-1 Env is highly confined at sites of assembly and diffuses freely when non-
proximal to the Gag lattice on the surface of infected CEM-A T-cells.  
(A) Representative examples of Env diffusion ‘Proximal’ and ‘Distal’ to sites of assembly 
(scale bars are 200 nm; Env: time-colored gradient; Gag: gray localization density). When 
proximal, Env was never observed to escape the Gag lattice over the sampling period, yet is 
able to freely diffuse when distal to assembly sites. Width of points represent uncertainty in 
localization of a single molecule in the time-series. (B) Histograms of the apparent diffusion 
coefficient (Dapparent) for proximal and distal tracks in log10 scale (Dapparent=0.04±0.02 
μm2× s−1 and 0.07±0.04 μm2×s−1, respectively). (C) Histograms of the slope of the moment 
scaling spectrum (SMSS) for proximal and distal tracks (SMSS=0.03±0.13 and 0.10±0.02, 
respectively). (D,E) Dapparent and SMSS for proximal versus distal trajectories were found 
to be statistically significant with a respective increase in both parameters for distal 
trajectories suggesting that Env trimers are less mobile and more sub-diffusive when 
proximal to a Gag lattice. Significance was assessed using a two-tailed unpaired t-test 
(PDapparent=2.67×10−17; PSMSS=1.04×10−15; α=0.0001; NProximal=476, NDistal=4089). 
















Next, we computed the apparent diffusion coefficient (Dapparent) and slope of the moment 
scaling spectrum (SMSS) for individual tracks, which mathematically describe the area 
covered by a single molecule in unit time and how well the molecule samples that area, 
respectively (Qian et al., 1991; Ferrari et al., 2001). There was a significant shift in 
both Dapparent and SMSS between proximal and distal tracks 
(PDapparent=2.67×10−17, PSMSS=1.04×10−15). D apparent for proximal tracks 
(0.042 μm2s−1) was roughly 40 percent lower than for distal tracks (0.068 μm2s−1), 
indicating that the Gag lattice acts as a net-like diffusion barrier for the Env trimers when 
incorporated. Apparent magnitude of a Gag bud is measured to tell how bright the assembly 
site appears at its distance from another separate assembly site. There was also a 70 
percent reduction in SMSS for proximal (0.028) versus distal tracks (0.099). Because 
the SMSS parameter indicates the shape or trajectory of a track as it samples an area of the 
membrane, a reduction in SMSS implies a more confined trajectory. 
An SMSS=0.028 and Dapparent=0.042μm2s−1 for proximal Env concludes that the tracks 
are highly confined, with sub-viral diffusion over the time frame of acquisition (≈30 s). 
Quantification of these parameters suggests that Gag has a significant influence on Env 
during virus assembly compared to distal Env trimers on the plasma membrane (Figure 9). 
The described methodology provides greater precision in the measurement of the Gag 
lattice perimeter, thus reducing the misclassification of proximal versus distal tracks and the 
associated error in diffusion measurements. Concurrently, our optimized BG18-QD625 probe 
enables tuneable high-density localization and tracking of single Env trimers on the surface 








Many aspects of virus biogenesis remain enigmatic due to our inability to resolved the 
time-variant structural organization of viral sub-assemblies while simultaneously maintaining 
molecular specificity and physiologically relevant conditions. Time-resolved superresolution 
approaches, however, offer promise to further our understanding of the molecular steps and 
sequences of events that transpire during virus assembly. In this study, we present a method 
for sub-viral quantification of biophysical interactions between single molecules of HIV-1 
envelope glycoproteins and the structural Gag lattice using live-cell single particle tracking 
and superresolution microscopy, respectively. This approach has allowed us to visualize 
nanoscale interactions between these molecules during virus biogenesis on the host-cell 
plasma membrane. We have shown that Gag lattices can be reconstructed to expected virus 
dimensions, below the diffraction-limit of the light microscope, using live-cell PALM. Further, 
we show that Env trimers can be simultaneously tracked and quantified based on their 
precise proximity to superresolved virus assembly sites. 
Our approach has relied on the use of a genetically-encoded cytoplasmically-expressed 
nanobody fused to a reversibly switchable fluorescent protein to reconstruct virus assembly 
sites. The success of live-cell PALM is highly dependent on how well the sub-diffractive 
object is decorated with a fluorescent probe. We show that the CA-Skylan-S nanobody probe 
sufficiently samples the Gag molecules in a single virus assembly site because each 
superresolved image over a 30 s time course yields a FWHM approximately the size of 
expected virus assembly sites measured by electron microscopy (Briggs et al., 2003). The 
success of live-cell PALM imaging additionally requires sufficient sampling of each 
fluorescent probe within the structure of interest and high molecular brightness to reduce the 
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uncertainty in the position of each probe. We judiciously selected the Skylan-S reversibly-
switchable green fluorescent protein for its single molecule brightness and switching 
frequency. Skylan-S enabled us to sufficiently sample each nanobody tagged probe a few 
times before bleaching irreversibly, while also giving a sufficiently high photon count for each 
frame to more precisely localize single molecule probes. Our attempts with other variants of 
the Skylan series of reversibly-switchable green fluorescent proteins resulted in either low 
molecular brightness and poor localization precision or poor switching properties resulting in 
a lack of blinking and single molecule detection (data not shown). Finally, live-cell 
superresolution reconstructions require careful consideration of physical displacements of 
the object of interest, requiring tuning of sampling conditions to reduce motion blur artifacts 
(Shroff et al., 2008; Huang et al., 2013). In the case of HIV-1 Gag lattice formation, this 
structure remains sufficiently static over the sampling period (30 s) as evidenced by the 
FWHM reconstructions and expected diameters of HIV-1 particles. 
Using our optimized fluorescent label and sampling conditions, we still, with minor 
frequency, found that our software filters out what is likely an assembly site that cannot be 
properly fit due to lack of localizations. Insufficient sampling at putative virus assembly sites, 
due to poor CA-Skylan-S probe labeling or sampling, may contribute to erroneous 
classifications of Env, resulting in an increase in apparent diffusion coefficient 
and SMSS distribution error. The sparsity of Env labeling with our methodology, however, 
statistically reduces the frequency of these false-negative events. 
Additional considerations for implementation of this methodology are the production of a 
recombinant antibody fragment, subsequent site-specific unnatural amino acid modification 
and copper-free click chemistry to a quantum dot (Figure 7 and Materials and Methods). 
While unnatural amino acid constructs are publicly accessible and quantum dot kits are 
commercially available, production of the probe in usable quantities can be costly and 
technical for adopters without recombinant protein chemistry experience. The BG18-QD625 
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probe described here is a prime example of a highly optimized recombinant protein 
expression protocol and tuned conjugation chemistry, which yields large quantities of stable 
probe that can be used for months to years. Ultimately, live-cell superresolution and SPT 
methodology requires highly specific and high affinity (sub-10 nM dissociation constant) 
monovalent reagents for labeling of biological structures of interest due to the intrinsic single 
molecule sensitivity of these experiments. 
The optimization of the CA-Skylan-S probe has provided a means for precise 
superresolution reconstructions of single HIV-1 assembly sites on the surface of live infected 
T-cells. Importantly, this resolution improvement has the potential to measure minor 
perturbations to Env mobility during lattice trapping. Further, our optimized production and 
validation of the BG18-QD625 probe has enabled us to tune the density of labeled Env 
trimers to maximize data collection on a per cell basis. This methodological advancement 
has provided insight into the biophysical interactions between the critical vaccine target HIV-
1 Env and the underlying Gag lattice that coalesce to create an infectious virus particle. The 
sub-diffusive nature of Env in the Gag lattice could indicate a direct interaction between the 
membrane proximal matrix (MA) domain of Gag and the cytoplasmic tail of Env (Env-CT). 
We cannot rule out a physical or steric corralling mechanism, however, which creates a 
diffusion barrier to trap Env in a sub-diffusive state within the lattice. Further work will be 
aimed at elucidating potential molecular interactions using the methodology we have 
presented. Studies investigating diffusional behaviours of viral envelope glycoproteins with 
their respective structural components should lead to discovery of new therapeutic 






Materials and Methods 
4.1. Reagents 
The HEK293T (CRL-3216) cell lines were obtained from ATCC (Manassas, VA, USA). 
The CEM-A cell line was obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: CEM-A from Dr. Mark Wainberg and Dr. James McMahon, CEM-CL10 
(Tremblay et al., 1989). Cell lines were grown at 37 ∘C with 5% CO2. Complete growth 
medium for HEK293T cells was prepared by combining 10% fetal bovine serum (Corning; 
Corning, NY, USA), 2 mM L-glutamine (Corning), and Penicillin-Streptomycin (Corning) into 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Corning) or for the CEM-A cell line with 
identical ingredients into Roswell Park Memorial Institute (RPMI) medium (Corning). 
Additionally, the CEM-A cell line growth medium was supplemented with 1% hypoxanthine, 
thymidine (HT) solution (Corning). 
4.2. Generation of CA-Skylan-S Expressing Viruses 
The pSV-NL4-3 reference HIV-1 genome was used for all experiments with constructs 
possessing deletions in the gag-p6 late-domain, pol, vif, vpr, and nef genes (Buttler et al., 
2018). To create viral vectors coexpressing the CA-Skylan-S nanobody, the coding region for 
the anti-CA nanobody was genetically fused to the Skylan-S gene with a coding amino acid 
linker of: ‘RSFEFCSRRYRGPGIHRPVAT’. The CA-Skylan-S probe cassette was amplified 
with 5′ and 3′ Gibson homology arms against the coding regions of the 3′ end of env and 
5′ end of the nef coding regions, respectively. Replication incompetent viruses harboring the 
CA-Skylan-S nanobody cassette in the nef splice site were produced by transfecting 
HEK293T cells with pSV-NL4-3 (described aboe) vector, pSPAX2 (Addgene, plasmid 
#12260), and pVSV-G (Addgene, plasmid #8454). Supernatants from cells expressing for 48 




4.3. Monovalent BG18-QD625 Production 
The BG18 anti-Env V3 glycan-binding light and heavy chain antibody sequences were 
obtained from the Protein Data Bank (6CH9) (Barnes et al., 2018). The fragment of antigen 
binding sequences were synthesized (IDT; Coralville, IA, USA) and cloned into the 
pCOMB3H-b12 vector using SacI and NotI sites, replacing the b12 fab coding sequence 
(Barbas et al., 1994). The pIII region of pCOMB3H was suppressed by introduction of a stop 
codon at the end of the BG18 heavy chain CH1 domain. The light chain gene fragment from 
BG18 was engineered to contain a 3′ amber stop codon (TAG) followed by a 6-fold repeat of 
histidine codons, finalized with an ochre stop codon (TAA). Periplasmic expression of BG18 
fab containing a C-terminal p-azido-L-phenylalanine (pAZF) unnatural amino acid (Bachem; 
Torrance, CA, USA) was performed in Escherichia Coli XL1 Blue competent cells 
(Stratagene; San Diego, CA, USA) by co-transformation with pCOMB3H-BG18-LC-Amber-
His6-Ochre and pEVOL-pAzF. Briefly, this strain was grown in 1–2 L of Super Broth medium 
containing selective antibiotics. At mid-log phase, 1 mM unnatural amino acid pAZF was 
added to the culture and expression of unnatural tRNAs and synthetase was induced with 
2% (w/v) L-arabinose (Gold Biotechnology; St. Louis, MO, USA). Cellular lysates were 
produced by sonication in PBS pH 7.4 supplemented with 0.2 mM PMSF (Gold 
Biotechnology). Soluble proteins were clarified via centrifugation at 30,000× g for 30 min and 
filtration by 0.22 μm cellulose acetate syringe filter. BG18 fab that successfully suppressed 
the amber stop codon with pAZF was purified using Nickel affinity chromatography (Gold 
Biotechnology) followed by purification using CaptureSelect CH1-XL affinity chromatography 
resin (Thermo Scientific; Waltham, MA, USA). Elution fractions were pooled and dialyzed 
overnight in PBS, pH 7.4. Expression was assessed (Figure7F) by SDS-PAGE analysis on 
4–20% gradient gel (Bio-Rad; Hercules, CA, USA). The final yields from 1–2 L of culture 
were typically in the range of 1–3 mg of BG18-pAzF. 
45 
 
Copper-free click chemistry was performed between DIBO-QD625 (Site-Click kit, Thermo 
Scientific) and BG18-pAzF using a 1:1.5-fold stoichiometry, respectively. The reaction was 
allowed to proceed for 12–18 h at room temperature in the dark. Uncoupled DIBO-QD625 
was removed from the reaction by another round of CaptureSelect CH1-XL affinity 
chromatography. Elution fractions were pooled and unreacted BG18-pAzF, lacking a DIBO-
QD625 conjugate, was removed by filtration through a 100 KDa molecular weight cutoff filter 
(Site-Click kit) followed by repeated buffer exchanges with PBS, pH 7.4. 
4.4. Sample Preparation and Imaging Conditions 
CEM-A T-cells in complete RPMI medium were dispensed onto 25 mm No. 1.0 glass 
coverslips (Warner Instruments; Hamden, CT, USA) at high density and allowed to adhere 
for 18–24 h at 37 ∘C and 5% CO2. Cells were infected with replication-incompetent (single-
round infection) virus and incubated for 38–46 h prior to imaging. Coverslips were transferred 
to specimen holders and mounted on a custom-built ring-TIRF microscope with an 
environmental chamber maintaining 37 ∘C and 5% CO2 previously described (Pezeshkian et 
al., 2019). Briefly, BG18-QD625 and CA-Skylan-S probes were both excited with 473 nm 
laser light (50 mW at rear aperture) and fluorescence was detected by separating the 
respective wavelengths with a dichroic beamsplitter and W-View Gemini image splitter 
(Hamamatsu, Hamamatsu City, Japan). Images of each channel were then focused onto two 
halves of a liquid cooled ORCA Fusion scientific-CMOS camera (C14440-20UP). Images 
were streamed at 100 Hz. 
4.5. Image Processing and Analysis 
All imaging, single molecule localization, and channel registration was done per 
Pezeshkian et. al., 2019 (Pezeshkian et al., 2019). Briefly, raw images were corrected for 
non-uniform pixel offset by use of a calibration map and were subsequently split based on 
wavelength. For CA-Skylan-S, frames with 10 ms exposure were integrated to 50 ms before 
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single molecule localization and fitting using custom software (IDL, Harris Geospatial; 
Broomfield, CO, USA). A high density map of bead localizations using TetraSpeck fiducials 
(Thermo Fisher Scientific) was used to create a polywarp transform using the cp2tform 
function in Matlab (Mathworks, Natick, MA, USA) to correct for lateral chromatic aberration 
between the channels. Single molecule localizations were then handed to an automated 
package written in MATLAB. CA-Skylan-S localizations with precision below 40 nm were 
used to reconstruct a 50 nm pixel size binned image. This image was sent through a cluster 
finding algorithm which extracted each Gag cluster centroid (window 150 × 150 nm) using a 
threshold that requires a minimum number of localizations and integrated probability density 
above 1 standard deviation from the background. Single molecule localizations of Env were 
then deemed proximal or distal to a Gag lattice by use of Equation (1). The separated 
localizations were then linked using a previously described track linking algorithm adapted to 
MATLAB from Crocker and Grier 1996 (Crocker et al., 1996). The parameters for linking are 
as follows: 50 ms time gap, 10 minimum localizations per track, 1 pixel (108.33 nm) 
maximum frame to frame distance. The remaining tracks were analyzed as previously 
described by using the moment scaling spectrum to 
calculate Dapparent and SMSS (Pezeshkian et al., 2019; Ferrari et al., 2001). Mean squared 
displacement (MSD) was fit to a linear regression solving for Dapparent using the lag 





Localization uncertainties were then used to weight the MSD fits (Equation (3)), where Ro is 
displacement and σR is standard deviation. 
 
                      (3) 
 
4.6. Monte Carlo Simulations of Single Molecule Localization and HIV-1 Assembly 
Site Reconstruction 
Simulations were performed using custom scripts written in MATLAB. Simulations were 
designed to assess the accuracy of reconstructions and centroid finding for scenarios with 
differing numbers of CA-Skylan-S probes per lattice and variances in molecular 
reappearance. CA-Skylan-S molecules were semi-randomly distributed on the surface of a 
sphere with a radius of 75 nm. Our simulations constrained the molecular positions to 
discontinuous regions between the polar angles (5π3,π3) and (2π3,4π3) to mimic the open 
neck of the viral bud and the increased accessibility of equatorial CA binding sites, 
respectively. True molecular positions were then shifted pseudo-randomly to mimic centroid 
uncertainty. This pseudo-random displacement vector was selected from a normal 
distribution centered around its position with a standard deviation of 50 nm, approximately 
the sum of our maximum localization uncertainty and standard deviation of our localization 
precision in experimental data (σmax=40±9 nm). Each simulation used a fixed number of 
molecular reappearances (α= 1 to 5) resulting in total localizations (1 to 50) to assess the 
accuracy of reconstruction. For each condition, 50 simulated assembly site X/Y-FWHM and 






 Introduction to Serinc5 
The serine incorporator protein 5 commonly known as, SERINC5 (SER5), is a host viral 
restriction factor that weakens HIV-1 infectivity by incorporating in newly formed virions and 
inhibiting Env mediated fusion with target cells (Sood et al., 2017). The mode of action of SER 5 
is currently unclear, however it has been confirmed that the MOA is related to Env inactivation 
and involves fusion events. SER 5 modifies the Env structure thereby exposing the virus to 
bNabs targeting immunogenic Env epitopes (Sood et al., 2017). SER 5 also has been shown to 
quicken the loss of Env function over time (Chen et al., 2020). Env clusters have been found on 
the surface of mature virions in many studies and SER 5 has also been shown to form clusters on 
the plasma membrane surface of single virions (Zhu et al., 2003; Buttler et al., 2018; Chen et al., 
2020). The incorporation of SER 5 perturbs Env clusters but does not downregulate the Env 
content thereby, explaining the likely mode of action of SER 5-mediated restriction of fusion 
(Chen et al., 2020). The Sood et al. group was able to demonstrate via fusion assays, the various 
impairments of fusion based on the Env genotype. The effect of SER 5 on HIV-cell fusion was 
tested by comparing the fusion activity of different pseudoviruses that contained and excluded 
SER 5 in their membrane and used inactive SER 2 as a negative control. As expected, results 
showed incorporated SER 5 had a significantly higher inhibitory effect on HIV-1 fusion as SER 2 




Measuring viral fusion in identical assays, it was shown that the cytoplasmic tail on gp41 
of Env, has no effect on inhibition in correlation with SER 5. With full expression of SER 5, a 
truncated Env cytoplasmic trimer tail, Δ CT, has shown significantly fewer fusion events than a full 
length Env trimer (Sood et al, 2017). These results explain the phenomena that is already known 
inregard to Env CT length and Gag interactions therefore, it is most likely the efficiency of Env 
incorporation into virus particles that explain the decrease in fusion events (Buttler et al., 2018; 
Bhakta, et al., 2011; Byland et al., 2007; Pezeshkian et al., 2019).  
Finally, potential Env inactivation and fusion disruption has been shown by using 
pseudoviruses containing SER 5 and tested to see if impairment occurred in the ability to form 
syncytia. Syncytia is a fusion event that has been demonstrated by HIV particles and other 
enveloped viruses, and is the process involving particles fusing to target cells in the absence of 
viral replication. This process is also referred to as “fusion from without” (Clavel & Charneau, 
1994). It was expectedly found that SER 5 containing viruses produced significantly less syncytia 
events compared to the SER 2 containing control viruses. SER 5 was expressed in the same 
ratio with Env as previous experiments mentioned above in the syncytia assays (Sood et al., 
2017).  
Though the antiviral mode of action of SER 5 is still to be completely understood, it has 
been demonstrated that there is an occurrence of SER 5-mediated restriction of fusion. 
Speculation has allowed for elucidation of other traits and dynamics of SER 5 and other key 
factors involved. The serine incorporator proteins are transmembrane proteins that pass through 
the membrane multiple times and are involved in serine incorporation into lipids and promotion of 
phosphatidylserine and sphingomyelin biosynthesis (Inuzuka, 2005). The HIV accessory protein 
known as Nef, is a player that can majorly impact pathogenicity as it is necessary for high virus 
loads and plays a role in infectivity (Usami et al., 2015). Nef’s mode of action is not completely 
understood either however, SER 5 has been observed to be antagonized by Nef. In a study using 
fluorescence microscopy and immunoprecipitation blotting the functionality effect of virion 
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infectivity was observed.  Using Jurkat Tag cells, a cell line with high responsiveness to Nef, and 
SER 5 genomic knockouts it was shown that SER 5 knockout cells produced a 20–30-fold 
increase in the infectivity of the Nef-defective HIV-1, whereas the Nef-positive virus was only 
affected 2–3-fold, thus reducing the Nef effect from 50- to 3-fold (Rosa et al., 2015).  
In conclusion, SER 5 recently has been characterized as an HIV-1 host restriction factor 
though its unique mechanism of restriction remains unclear. With the information that is known it 
can be concluded that in order to investigate SER 5, an extracellular probe and live cell time 
lapsed assembly and post-assembly assays will be essential to the discovery of the mechanism 
of action. 
SER5 KI & HA Tag 
To present day, there remains a search for antibodies with sensitivity and specificity for 
the investigation of SER 5. Currently, CRISPR/Cas9 gene editing development has yielded a 
human T-cell line, Jurkats, allowing for the endogenous expression of SER 5, with an exposed 
extracellular HA epitope [JurkatSERINC5(iHemagglutinin (HA) knock-in) T cells]. These SER 5 
iHAknock-in cells equaled the parental Jurkat cells in their ability to produce infectious wild-type 
HIV-1 but not an HIV-1 Δnef mutant (Passos et al., 2019). Using CRISPR-Cas9 as a 
manipulatable tool for site-specific gene editing  has enabled tagging of endogenous proteins in 
human cells (Cong et al., 2013; Mali et al., 2013; Ratz et al., 2015). With a shortage of SER 5 
antibodies available and an abundance of HA antibodies on the market, an HA knock-in 
expression increases the likelihood of finding a desirable tracking probe for SER 5. The 
extracellular HA epitope serves as an ideal target for a molecular fluorescently labeled probe to 
investigate SER 5 and its role in HIV-1 restriction, as an intracellular probe. 
Hemagglutinin (HA) is the major surface envelope glycoprotein of an influenza virion, and 
its mechanism of action serves as virus entry into the host cell to initiate infection (Smith et al., 
2004). The HA tag is a short peptide consisting of 9 amino acids which correspond to residues 
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98-106 of the human influenza HA molecule (Zhao, 2015). The HA tag is popularly used as 
an epitope tag in expression vectors and allows for the detection, isolation, and purification of 
proteins as there are many commercial monoclonal and polyclonal HA antibodies available for 
purchase. It also has been shown that recombinant proteins are commonly cloned with the HA 
epitope tag as it does not appear to interfere with the protein’s bioactivity or function (Zhao, 
2015). Overall, an HA tag serves as an ideal epitope for the protein of interest, SER 5, to allow for 
investigation of the mechanism of action. 
In the search for therapeutic broadly neutralizing antibodies for influenza A virus strains, 
phage display technology was used to select single-chain variable fragments (scFv) recognizing 
the influenza envelope protein, HA. After several rounds of phage display, one of the HA ScFvs in 
trial was selected for preparative-scale production as soluble antibody by E. coli. It has been 
determined that the complementarity-determining region of the variable heavy chain (VH-CDR2) 
binds the stem region of HA (Li et al., 2015). The development of an HA ScFv has served as a 
powerful tool for neutralization, detection, and tracking proteins of interest.  
Overall, it was predicted that this HA ScFv would serve as an ideal candidate for 
fluorescently labeling and tracking SER 5. Our studies have investigated further into the 
mechanism of SER 5 with this monovalent fluorescently labeled HA ScFv-QD625 and Jurkat 
SERINC5(iHA knock-in) T cells. Single particle tracking and TIRF microscopy can be used to 
investigate SER 5’s role in assembly and maturation to answer the following questions: Is Gag a 
major contributor to SER 5 incorporation? Is the diffusion and mobility of Env within the lipids of 
the plasma membrane affected by SER 5 due to hardening of the membrane and therefore fusion 
is affected as well as pore size formation? What does Env mobility look like in the presence and 
absence of Gag along with SER 5? Does the mechanism by which the fusion pore is affected 
slow down the fusion event all together? If this is the case and fusion is slowed, gp41 will remain 
in its “open” conformational state allowing Env to be more exposed for a longer time potentially 
exposing binding sites for neutralizing antibodies. To investigate Env and Gag interactions with 
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SER 5, immunolabeling during infection and live cell imagining will allow for the reveal of single 
particle tracking and protein-protein interactions. 
Materials and Methods 
a. Cloning of anti-HA ScFv 
The pCOMB-3H-b12 plasmid (Addgene; Barbas et al., 1994) is digested with SacI and BglII 
restriction enzymes for 12 hours at 37℃ and purified using a Monarch Gel Extraction Kit (NEB). 
The anti-HA ScFv design can be found in the appendix. The DNA fragment containing anti-HA 
ScFv antigen binding sequences were synthesized (IDT; Coralville, IA, USA) and cloned into the 
pCOMB3H-b12 vector using SacI and BglII sites, replacing the b12 fab coding sequence (Barbas 
et al., 1994). The pIII region of the anti-HA ScFv Heavy and Light chain genes were amplified 
from a designed gBlock (IDR) with primers carrying SacI and BglII sites, containing pCOMB 
homology. Amplicons were ligated via Gibson reaction into the opened pCOMB vector. All 
sequencing was confirmed and validated through Quintara Biosciences.  
b. Test Expressions 
Immediately following DNA sequence validation, transformation of the pCOMB-3H-BG18 
plasmid is performed in Escherichia Coli XL1 Blue competent cells (Stratagene; San Diego, CA, 
USA). This strain is plated on LB agar containing the selective antibiotic, carbenicillin, and 
incubated overnight for approximately 16-18 hours at 37°C. A population of bacterial colonies 
(n>6), is selected for and each colony is inoculated into 1 X 5 mL LB broth media containing 
carbenicillin (100 µg/ml), tetracycline (15 µg/ml) and dextrose (.02 M). Incubation then occurs 
overnight at 37°C in a shaking incubator at ~220-250 RPM. After 16-18 hours, observe cultures to 
ensure a moderate amount of growth and biofilm production. Measure the OD600 and select for 
the culture amongst the population that nears the OD600 of 0.3 A. Once the ideal culture has been 
determined, discard the remainder of the population. The entire 5 mLs of the overnight culture will 
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then be used to inoculate 2 x 50 mL Super Broth medium containing carbenicillin (100 µg/ml) and 
tetracycline (15 µg/ml) in a 250-mL flask for appropriate aeration and 2 x 50 mL Luria Broth 
medium containing carbenicillin (100 µg/ml) and tetracycline (15 µg/ml) in a 250-mL flask for 
appropriate aeration. To inoculate, spin 5 mL cultures at 4,000 xg for 5 minutes, pour off and 
discard the supernatant and vortex pellet with 1 mL of Phosphate-Buffered Saline, pH 7.4 (PBS). 
Repeat this PBS cell wash step 3 times. After discarding the final wash supernatant, 1 mL of LB 
is added to the pellet which is then vortexed thoroughly. 250 uLs of vortexed culture is then 
added to the 50 mLs of SB and LB broth flasks and swirled to mix evenly. Cultures are then 
grown at 37°C until mid-log phase of growth (OD600 is approximately 0.6 A) which is a timed 
averaged of approximately 8 h After mid-log phase has been reached, 2 of the flasks will be 
removed from the 37°C and placed into a 30°C shaking incubator with equivalent RPM. Cultures 
are then shaken and grown overnight for 16-18 h The cells are harvested by normalizing the 
OD600 to the limiting culture and then pouring the cultures into 50 mL conical tubes and spun for 
20 min at 6,000 x g using a Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge 
(Thermo Scientific).  The pellet is then washed (3 X 30 mL [1X] PBS). Store the pellet at -80°C for 
at minimum of 1 hour. Note: storage time can be up to 1 year.  
Cellular lysates were produced by sonication in PBS pH 7.4 supplemented with 0.2 mM 
PMSF (Gold Biotechnology). Soluble proteins were clarified via centrifugation at 30,000× g for 30 
min and filtration by 0.22 μm cellulose acetate syringe filter. Use a large probe, preferably the 
300w Ultrasonic Homogenizer sonicator with the following settings: cycle 40% output power 1 
minute ON and 4 minutes OFF (Vevor). Centrifugation was performed using the same Fiberlite 
F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge (Thermo Scientific). Note: It is very 
important at this step to ensure your centrifuge balance is equivalent in mass to that of the 




c. Coomassie Blue Stain 
After lysis, proteins are loaded and separated by a 4-20% polyacrylamide gel (Bio-Rad). Gel 
is then fixed in 50% MeOH, 10% AcOH, and 40% H2O for by rocking at room temperature for 30 
minutes. Immediately following fixing, the gel is then stained in 50% MeOH, 10% AcOH, 39.75% 
H2O and 0.25% Coomassie Blue by rocking at room temperature for 5 minutes. An overnight 
destain is performed with 5% MeOH, 7.5% AcOH and 87.5% H2O, in which the gel should be 
analyzed and then can store indefinitely. 
a. HA Peptide Affinity Chromatography Purification 
HA resin was created by covalently linking NHS activated dry agarose resin beads 
(ThermoScientific) to the HA peptide (Sigma Aldrich). To create a 0.5 mL resin bed, 1 mg of HA 
peptide was dissolved in 1 mL of [1X] PBS pH 7.4 and coupled to 75 mg of dry agarose beads. 
Protocol for NHS coupling can be found: 
https://www.thermofisher.com/order/catalog/product/26196#/26196. 
Create and pack a 0.5 mL resin bed of freshly prepared HA affinity chromatography resin in a 
Flex Column, equilibrated to room temperature with running buffer (Kimble). Running buffer 
consists of [1X] PBS, pH 7.4, .05% (v/v) TWEEN and .05% w/v sodium azide. Pour 20 mL cell 
lysate at a time over the resin bed carefully collecting the flowthrough. The column is washed with 
≥ 300 mL running buffer before eluting the protein while simultaneously collecting flowthrough 
fractions. Ensure that the flow rate of running buffer does not exceed 2 mLs/min. To elute the 
protein from the column, 5 mL .2 M glycine at a pH of 2.2 is slowly poured over the matrix and 
neutralized in 1 M Tris pH 9 to yield a collected fraction at a neutral pH of 7.4. Note: volume of the 
fraction is variable based entirely on preference. Elution fractions were pooled and dialyzed 
overnight in PBS, pH 7.4 with SnakeSkin dialysis tubing at 4°C (Thermo Scientific). Expression is 
assessed by SDS-PAGE analysis on 4–20% gradient gel (Bio-Rad; Hercules, CA, USA). Protein 
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concentration can also be analyzed by calculating the absorbance at 280 nm and utilizing the 
Beer-Lambert Law. 
f. Scale-up: Production of HA-ScFv (1L) 
Construct used: N-terminal Light Chain gene with C-terminal His-6 tag on Heavy Chain in 
a pCOMB vector (ampicillin/carbenicillin resistance). 
Construct name: pCOMB3H-[HA-ScFv] 
The construct is newly transformed into E. coli XL1Blue cells or plated from a glycerol 
stock of freshly transformed XL1Blue cells (Stratagene; San Diego, CA, USA). The cells are 
plated out on LB-agar containing ampicillin (100 µg/ml) and tetracycline (15 µg/ml). Incubation 
then occurs overnight for 16-18 h at 37°C. A colony is selected from the plate to inoculate 1 X 5 
mL LB medium containing carbenicillin (100 µg/ml), tetracycline (15 µg/ml) and dextrose (.02 M). 
Incubation then occurs overnight at 37°C in a shaking incubator between 220-250 RPM. At the 
point of overnight growth after , the 5 mL culture will then be used to inoculate 1 x 1 L Super 
Broth medium containing carbenicillin (100 µg/ml) and tetracycline (15 µg/ml) in a 2-L flask for 
appropriate aeration. After 16-18 hours, observe culture to ensure a moderate amount of growth 
and biofilm production. Measure the OD600 of culture and make note for future optimization. Ideal 
OD600 is approximately 1.5 A. The entire 5 mL of the overnight culture will then be used to 
inoculate 1 x 1 L SB broth medium containing carbenicillin (100 µg/ml) and tetracycline (15 µg/ml) 
in a 2 L flask for appropriate aeration. To inoculate, spin 5 mL culture at 4,000 xg for 5 minutes, 
pour off and discard the supernatant and vortex pellet with 1 mL of PBS. Repeat this PBS cell 
wash step 3 times. After discarding the final wash supernatant, 1 mL of LB is added to the pellet 
which is then vortexed thoroughly. The entire 1 mL of vortexed culture is then added via pipette to 
the 50 mLs of SB broth and swirled to mix evenly. Cultures are then grown at 37°C until mid-log 
phase of growth (OD600 is approximately 0.6 A) with a timed averaged of approximately 6 h After 
mid-log phase has been reached, the flask will be removed from the 37°C and placed into a 30°C 
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shaking incubator with equivalent RPM. Cultures are then shaken and grown overnight for 16-18 
h Harvest is performed by pouring the cultures into 500 mL centrifuge bottles and spun for 20 min 
at 6,000 x g using a Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge (Thermo 
Scientific).  The pellet is then washed (3 X 30 mL [1X] PBS) and recollected into a 50 mL conical 
tube. Store the pellet at -80°C for a minimum of 1 hour. Note: storage time can be up to 1 year.  
Cellular lysates were produced by sonication in PBS pH 7.4 supplemented with a final 
concentration of 0.2 mM PMSF (Gold Biotechnology). Soluble proteins were clarified via 
centrifugation at 30,000× g for 30 min and filtration by 0.22 μm cellulose acetate syringe filter. 
Use a large probe, preferably the 300w Ultrasonic Homogenizer sonicator with the following 
settings: cycle 40% output power 1 minute ON and 4 minutes OFF (Vevor). Centrifugation was 
performed using the same Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall centrifuge 
(Thermo Scientific). Note: It is very important at this step to ensure your centrifuge balance is 
equivalent in mass to that of the sonicated lysate. Cell lysate now contains solubilized HAScFv to 
be purified via CaptureSelect CH1-XL affinity chromatography resin (Thermo Scientific; Waltham, 
MA, USA). 
g. Incorporated Unnatural Amino Acid Production (1 L)  
Construct(s) used: N-terminal Light Chain gene with C-terminal Amber- His-6 tag on 
Heavy Chain preceding Ochre in a pCOMB vector (ampicillin/carbenicillin resistance). 
And a tRNA/tRNA synthetase pair for the in vivo incorporation of the negatively charged 
unnatural amino acid, p-azido-l-phenylalanine, onto HA-ScFv heavy chain in E. coli response to 
the Amber stop codon, encoded in a pEVOL vector (chloramphenicol resistance). 
Construct(s) name:  pCOMB3H-HAScFv-LC-Amber-His6-Ochre and pEVOL-pAzF [1]. 
The constructs are newly co-transformed into E. coli XL1Blue cells or plated from a 
glycerol stock of freshly transformed XL1Blue cells (Stratagene; San Diego, CA, USA). The cells 
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are plated out on LB-agar containing ampicillin (100 µg/ml), tetracycline (15 µg/ml) and 
chloramphenicol (33 µg/ml). Incubation then occurs overnight at 37°C. A colony is selected from 
the plate to inoculate 1 X 10 mL LB medium containing carbenicillin (100 µg/ml), tetracycline (15 
µg/ml), chloramphenicol (33 µg/ml) and a final concentration of .02 M dextrose. Incubation then 
occurs overnight for 18-18 h at 37°C in a shaking incubator at 220-250 RPM. The entire 10 mL of 
the overnight culture will then be used to inoculate 1 x 1 L SB broth medium containing 
carbenicillin (100 µg/ml), tetracycline (15 µg/ml) and chloramphenicol (33 µg/ml) in a 2 L flask for 
appropriate aeration. To inoculate, spin the 10 mL starter culture at 4,000 xg for 5 minutes, pour 
off and discard the supernatant and vortex pellet with 5 mL of PBS. Repeat this PBS cell wash 
step 3 times. After discarding the final wash supernatant, 1 mL of LB is added to the pellet which 
is then vortexed thoroughly. The entire 1 mL of vortexed culture is then added via pipette to the 1 
L of SB broth and swirled to mix evenly. Cultures are then grown at 37°C until mid-log phase of 
growth (OD600 is approximately 0.6 A) which is a timed averaged of approximately 5 h After mid-
log phase has been reached, 1 mM 4-Azido-L-phenylalanine (pAZF) was supplemented to the 
culture and expression of unnatural tRNAs and synthetase was induced with 2% (w/v) L-
arabinose (Gold Biotechnology; St. Louis, MO, USA). Cultures are then shaken and grown 
overnight for 16-18 h Harvest is performed by pouring the cultures into 500 mL centrifuge bottles 
and spun for 20 min at 6,000 x g using a Fiberlite F13-14 x 50cy Fixed-Angle rotor in a Sorvall 
centrifuge (Thermo Scientific).  The pellet is then washed (3 X 30 mL [1X] PBS) and recollected 
into a 50 mL conical tube. Store the pellet at -80°C for a minimum of 1 hour. Note: storage time 
can be up to 1 year. HA ScFv that successfully suppressed the amber stop codon with pAZF was 
purified using Nickel affinity chromatography (Gold Biotechnology) followed by purification using 
HA peptide affinity chromatography resin (Thermo Scientific; Waltham, MA, USA). Elution 
fractions were pooled and dialyzed overnight in PBS, pH 7.4. Expression was assessed by SDS-
PAGE analysis on 4–20% gradient gel (Bio-Rad; Hercules, CA, USA). The final yields from 1–2 L 





h. Ni2+ Polyhistidine Affinity Chromatography Purification 
Cell lysis is to be performed in Buffer A, a solution adjusted to pH 8.0 containing 20 mM 
HEPES, 300 mM NaCl, 300 mM KCl and 20 mM imidazole. The Ni2+ resin is then equilibrated 
with Buffer A and batch incubated with the lysate over ice. To batch incubate, use desired amount 
of resin and resuspend 1 mL Buffer A and combine with cell lysate in 50 mL conical tube and rock 
slowly on ice for ≥ 1 h. Using a drip column, the resin is poured slowly to pack the column while 
the flowthrough is collected for future analysis. Wash the column with 12 column volumes of 
Buffer A solution, occasionally collecting flowthrough fractions for analysis. To elute, use 5 mL 
Buffer A containing 250 mM imidazole, collecting 1 mL fractions in 1.5 mL Eppendorf tubes. 
Elution fractions were pooled and dialyzed overnight in PBS, pH 7.4 with SnakeSkin dialysis 
tubing at 4°C (Thermo Scientific). Expression is assessed by SDS-PAGE analysis on 4–20% 
gradient gel (Bio-Rad; Hercules, CA, USA). Protein concentration can also be analyzed by 
calculating the absorbance at 280 nm and utilizing the Beer-Lambert Law. 
j. DIBO Cu-free Click Reaction 
Copper-free click chemistry was performed between DIBO-QD625 (Site-Click kit, Thermo 
Scientific) and BG18-pAzF using a 1:1.5-fold stoichiometry, respectively. The reaction could 
proceed for 12–18 h at room temperature in the dark. Uncoupled DIBO-QD625 was removed 
from the reaction by another round of CaptureSelect CH1-XL affinity chromatography. Elution 
fractions were pooled and unreacted BG18-pAzF, lacking a DIBO-QD625 conjugate, was 
removed by filtration through a 100 Kda molecular weight cutoff filter (Site-Click kit) followed by 







It has been shown that SER 5 does play a role in fusion however, the mode of action is 
yet to be completely understood. I have created tools to investigate Env-dependent SER 5 
protein-protein interactions via single particle tracking by TIRF superresolution microscopy.  
Investigations of mode of actions have found several suggestions for SER 5 such as that 
of Env proteins from tier 2/3 isolates have been suggested to antagonize SER 5 more efficiently 
than Nef (Beitari et al., 2017). These strains of Env were then further studied and have shown 
sensitivity to SER 5 upon production in the presence of CD4 (Zhang et al., 2017). 
Contrary to the investigation of the antagonistic method, SER 5 has been found to keep 
Env forced in its closed conformation. When CD4 is absent, native tier 1 Env trimers 
preponderantly are found to be in the open conformation, as the native tier 2/3 Env trimers 
preserve the closed conformation (Munro et al., 2017; Munro and Mathes, 2015). 
Using a dual quantum dot tracking assay, Env-Env associations, SER 5-Env interactions 
and SER 5-Gag interactions can al all be preformed with the generated probes, BG18-QD525 
Fab and anti-HA-QD605 ScFv as well as a previously generated CANTD-SkylanS (Figure 6 and 
Figure 11). Subcellular colocalization of all 3 proteins: Env, Gag and SER 5 can be quantified, 
and protein-protein interactions can be easily observed with single particle tracking. The two 
quantum dot probes, BG18 Fab and anti-HA ScFv are advantageous for many reasons however, 
their brightness and direct antigen binding specificity allow for the measure of precise and 
accurate direct interactions between the two proteins of interest—Env and SER 5.  
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Because CD4 is also a key player in Env conformation, if the recombinant production of 
CD4 is to be successful, the various levels of CD4 required for Env sensitivity to SER 5 can also 
be investigated upon the application of single particle tracking. Gag is another component needed 
at sites of assembly for HIV-1 replication, and there are currently no investigations reporting SER 
5 interactions with Gag (Buttler et al., 2018). Therefore, it is possible that SER 5 could potentially 
serve as an antiviral host factor at the site of viral assembly. 
The results obtained from the production of a dual quantum dot single particle tracking 
assay will yield important findings and suggestions for understanding the unknown Env-
dependent or Gag-dependent SER 5 host anti-viral mode of action. My hypothesis parallels that 
of a recent finding that SER 5 disrupts the clustering of Env trimers (Firrito et al., 2018). If the 
clustering of Env trimers are disrupted, then the required interactions between Env and Gag 
downstream would also become disrupted. A disruption between Gag and Env would thereby 
explain an antiviral mechanism of action of SER 5 to be that of assembly disruption. 
Overall, more effort is needed to comprehend protein interactions of Ser 5, Env, Gag and 










Figure 4.1. Figure 10. Native baseline expression of SER 5 on the surface of SER 5 
iHAknock-in Jurkat cells  
Representative image of whole Jurkat cells producing an extracellular HA epitope on 
SER 5. SER 5 was detected via anti HA-Atto565 ScFv and fixed and labeled for surface-






Figure 4.2. Native Jurkat cells stained with the anti-HA ScFv-Atto565 probe.  
Negative control for immunostaining with the anti-HA ScFv-Atto565 fluorescent probe. Images of 






















Figure 4.3. Env and SER 5 labeled at the cell surface could have correlation relative to Env 
diffusion. 
Fixed Jurkat cells expressing WT-Env and iHA knock-ins were labeled with both anti-Env Fab 
BG18-QD525 (green) and anti-HA ScFv QD625 (red) and then fixed after labeling to demonstrate 
any Env and SER 5 correlation. In Jurkat cells, surface Env appears to have a correlation with 
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